Halozyme Therapeutics company profile
Company profile
Halozyme Therapeutics has 423 employees and is headquartered in San Diego, United States.
Halozyme is known for Hylenex and XYOSTED, and for its patented recombinant human hyaluronidase enzyme, rHuPH20, which lets injectable biologics be delivered under the skin. Its partners market subcutaneous versions of well-known cancer, autoimmune and immunodeficiency therapies, including Herceptin Hylecta, Phesgo, Tecentriq SC, Ocrevus SC, HYQVIA and DARZALEX, and the company also works with argenx, Pfizer, AbbVie and Eli Lilly. Its licensing collaborations and its own proprietary enzymes and devices reach markets in the United States, Switzerland, Belgium, Japan and beyond.
In the fiscal year ended December 2025, Halozyme reported revenue of USD 1.4 billion, up 37.6% from the previous year, and net income of USD 316.9 million. The company had 423 employees and is headquartered in San Diego, California, where it was founded in 1998. Its shares also trade on other exchanges.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 12390 El Camino Real, 92130, San Diego
- Employees
- 423
- Chief executive
- Helen Torley
- Founded
- 1998
- Fiscal year
- January - December
- Listing
- HALO · NASDAQ
- Currency
- USD
- ISIN
- US40637H1095
- Website
- halozyme.com
Halozyme Therapeutics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Halozyme TherapeuticsHALO | United States | $14.67B | 423 | 56.8% | 38.3 |
| BridgeBio PharmaBBIO | United States | $15.25B | 1,081 | -37.3% | — |
| Jazz PharmaceuticalsJAZZ | United States | $15.5B | 2,890 | 27.4% | 71.5 |
| ExelixisEXEL | United States | $16.37B | 1,077 | 40.2% | 20.1 |
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
